Navidea Biopharmaceuticals Inc (NAVB) Short Interest Update

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 4,491,078 shares, an increase of 9.2% from the January 12th total of 4,112,919 shares. Currently, 2.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 236,822 shares, the days-to-cover ratio is currently 19.0 days.

A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. Virtu KCG Holdings LLC increased its position in shares of Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 305.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 336,414 shares of the biopharmaceutical company’s stock after purchasing an additional 253,471 shares during the quarter. Virtu KCG Holdings LLC owned approximately 0.21% of Navidea Biopharmaceuticals worth $172,000 at the end of the most recent quarter.

Shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) remained flat at $$0.35 during mid-day trading on Friday. 550,323 shares of the company’s stock traded hands, compared to its average volume of 291,254. Navidea Biopharmaceuticals has a twelve month low of $0.29 and a twelve month high of $0.85. The company has a market cap of $58.46, a price-to-earnings ratio of -5.00 and a beta of -0.76.

Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. Navidea Biopharmaceuticals had a negative net margin of 688.85% and a negative return on equity of 38.60%. The business had revenue of $0.22 million during the quarter.

TRADEMARK VIOLATION NOTICE: This news story was first posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease.

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply